Exact Mass: 211.1143

Exact Mass Matches: 211.1143

Found 7 metabolites which its exact mass value is equals to given mass value 211.1143, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

Pramipexole

6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate

C10H17N3S (211.1143)


Pramipexole is a medication indicated for treating Parkinsons disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist. D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D020011 - Protective Agents > D000975 - Antioxidants Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

   

Dexpramipexole

6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate

C10H17N3S (211.1143)


   

Pramipexole

(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

C10H17N3S (211.1143)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D020011 - Protective Agents > D000975 - Antioxidants Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

   

4-(azepan-1-ylmethyl)-1,3-thiazol-2-amine

4-(azepan-1-ylmethyl)-1,3-thiazol-2-amine

C10H17N3S (211.1143)


   

Dexpramipexole

Dexpramipexole

C10H17N3S (211.1143)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D020011 - Protective Agents > D000975 - Antioxidants

   

3-cyclohexyl-4-ethyl-1H-1,2,4-triazole-5-thione

3-cyclohexyl-4-ethyl-1H-1,2,4-triazole-5-thione

C10H17N3S (211.1143)


   

N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

C10H17N3S (211.1143)